Tekmira Faces Fall In Short Interest But Maintains A Buy Rating
Tekmira Pharmaceutical Corporation faces a fall in the short interest shares by around 1.1%. A drop of total 40, 155 shares was faced by the company. As on 15th January, the short position shares dropped from 3,519,240 to 3,479,085 on 30th January, 2015.
The floated stock’s final interest came out to be 16.9%. A total exchange of 933,791 shares was recorded for the day of Wednesday, 11th February 2015.
The medicine making Tekmira company faced a temperamental day at the trading session as of 11th February 2015. The Company ended the session with an unexpected decline of 0.71 points or 3.13%.
The expectations of the bulls did not soar high and were rather disappointed when the stock price increased only a little over the opening price but failed to maintain the position and eventually fell way below it at the closing time.
The share price that the company opened at for the day was $22.53 and during the trading session, the price only reached till $22.77 and then did not increase again. The last transaction in the session was made for $21.95 as the maximum level that the share price reached acted as a support.
The volume of the shares saw an accession of 432,552 shares. The previous closing price of the company was recorded at $22.66. $8.86 was the share price that was recorded at the 52 day low of the company. The company’s total market revenue values up at $493 million.
Tekmira Pharmaceutical (NASDAQ:TKMR) received a concurrent rating of ‘hold’ from seven equity firms. Two financial analysts have given the firm the rating of a ‘sell’, whereas 5 financial firms have declared the company’s shares to be of ‘buy’ rating.
Analysts have given the average price target for the shares of the company to be $27.63 for the 12-month period.
Tekmira’s 50-day moving average of the stock is $20.47 and the average for 200 day moving stock is $18.58.
Recently, analysts at RBC Capital raised their price target on the company’s shares from $25.00 to $35.00, declaring the company’s financial activity to be an ‘outperform’. Financial analysts at Leerink Swann elevated Tekmira’s shares from a rating of ‘market perform’ to an ‘outperform’. The analysts at Maxim increased their price target on the company’s shares from $21.00 to $27.00.
Tekmira is a company that deals in creating medicine for many diseases and gives technological assistance regarding medicine to many other companies.
